SE509350C2 - Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation - Google Patents
Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantationInfo
- Publication number
- SE509350C2 SE509350C2 SE9603082A SE9603082A SE509350C2 SE 509350 C2 SE509350 C2 SE 509350C2 SE 9603082 A SE9603082 A SE 9603082A SE 9603082 A SE9603082 A SE 9603082A SE 509350 C2 SE509350 C2 SE 509350C2
- Authority
- SE
- Sweden
- Prior art keywords
- hyaluronidase
- treatment
- hyaluronan
- mammal
- medicament
- Prior art date
Links
- 108010003272 Hyaluronate lyase Proteins 0.000 title claims abstract description 23
- 102000001974 Hyaluronidases Human genes 0.000 title claims abstract description 23
- 229960002773 hyaluronidase Drugs 0.000 title claims abstract description 23
- 206010030113 Oedema Diseases 0.000 title claims abstract description 15
- 210000000056 organ Anatomy 0.000 title claims abstract description 13
- 238000002054 transplantation Methods 0.000 title claims description 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 21
- 229940099552 hyaluronan Drugs 0.000 claims abstract description 21
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 230000037396 body weight Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000009885 systemic effect Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603082A SE509350C2 (sv) | 1996-08-26 | 1996-08-26 | Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation |
| ES97934835T ES2183206T3 (es) | 1996-08-26 | 1997-07-24 | Uso de hialuronidasa. |
| PCT/SE1997/001313 WO1998008538A1 (en) | 1996-08-26 | 1997-07-24 | Use of hyaluronidase |
| EP97934835A EP0942745B1 (de) | 1996-08-26 | 1997-07-24 | Verwendung von hyaluronidase |
| DE69715898T DE69715898T2 (de) | 1996-08-26 | 1997-07-24 | Verwendung von hyaluronidase |
| CA002262637A CA2262637C (en) | 1996-08-26 | 1997-07-24 | Use of hyaluronidase |
| AU37908/97A AU721141B2 (en) | 1996-08-26 | 1997-07-24 | Use of hyaluronidase |
| AT97934835T ATE224729T1 (de) | 1996-08-26 | 1997-07-24 | Verwendung von hyaluronidase |
| JP51152798A JP4087453B2 (ja) | 1996-08-26 | 1997-07-24 | ヒアルロニダーゼの使用 |
| NO19990898A NO325945B1 (no) | 1996-08-26 | 1999-02-25 | Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603082A SE509350C2 (sv) | 1996-08-26 | 1996-08-26 | Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9603082D0 SE9603082D0 (sv) | 1996-08-26 |
| SE9603082L SE9603082L (sv) | 1998-02-27 |
| SE509350C2 true SE509350C2 (sv) | 1999-01-18 |
Family
ID=20403654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9603082A SE509350C2 (sv) | 1996-08-26 | 1996-08-26 | Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0942745B1 (de) |
| JP (1) | JP4087453B2 (de) |
| AT (1) | ATE224729T1 (de) |
| AU (1) | AU721141B2 (de) |
| CA (1) | CA2262637C (de) |
| DE (1) | DE69715898T2 (de) |
| ES (1) | ES2183206T3 (de) |
| NO (1) | NO325945B1 (de) |
| SE (1) | SE509350C2 (de) |
| WO (1) | WO1998008538A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2413492T3 (es) | 2008-10-14 | 2013-07-16 | Burgard, Gunther, Dr. | Uso de hialuronidasa para la prevención o el tratamiento de la hipertensión arterial |
| EP2392325A1 (de) | 2010-06-04 | 2011-12-07 | Universitätsklinikum Münster | Neue Verbindungen zur Prävention und/oder Behandlung von Osteoarthrose |
-
1996
- 1996-08-26 SE SE9603082A patent/SE509350C2/sv not_active IP Right Cessation
-
1997
- 1997-07-24 WO PCT/SE1997/001313 patent/WO1998008538A1/en not_active Ceased
- 1997-07-24 AT AT97934835T patent/ATE224729T1/de not_active IP Right Cessation
- 1997-07-24 DE DE69715898T patent/DE69715898T2/de not_active Expired - Lifetime
- 1997-07-24 JP JP51152798A patent/JP4087453B2/ja not_active Expired - Fee Related
- 1997-07-24 EP EP97934835A patent/EP0942745B1/de not_active Expired - Lifetime
- 1997-07-24 ES ES97934835T patent/ES2183206T3/es not_active Expired - Lifetime
- 1997-07-24 CA CA002262637A patent/CA2262637C/en not_active Expired - Fee Related
- 1997-07-24 AU AU37908/97A patent/AU721141B2/en not_active Ceased
-
1999
- 1999-02-25 NO NO19990898A patent/NO325945B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0942745B1 (de) | 2002-09-25 |
| NO990898D0 (no) | 1999-02-25 |
| CA2262637A1 (en) | 1998-03-05 |
| WO1998008538A1 (en) | 1998-03-05 |
| AU721141B2 (en) | 2000-06-22 |
| JP2000517315A (ja) | 2000-12-26 |
| DE69715898T2 (de) | 2004-01-22 |
| NO325945B1 (no) | 2008-08-25 |
| CA2262637C (en) | 2004-03-30 |
| NO990898L (no) | 1999-02-25 |
| ATE224729T1 (de) | 2002-10-15 |
| SE9603082L (sv) | 1998-02-27 |
| SE9603082D0 (sv) | 1996-08-26 |
| EP0942745A1 (de) | 1999-09-22 |
| DE69715898D1 (de) | 2002-10-31 |
| ES2183206T3 (es) | 2003-03-16 |
| AU3790897A (en) | 1998-03-19 |
| JP4087453B2 (ja) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tobeiha et al. | Evidence for the benefits of melatonin in cardiovascular disease | |
| St-Pierre et al. | Comparative analysis of maple syrup to other natural sweeteners and evaluation of their metabolic responses in healthy rats | |
| Beznák | The effect of the pituitary and growth hormone on the blood pressure and on the ability of the heart to hypertrophy | |
| Li et al. | Anti-inflammatory activity of polysaccharide from Pholiota nameko | |
| Uddandrao et al. | Therapeutical perspectives of S-allylcysteine: effect on diabetes and other disorders in animal models | |
| Li et al. | Vitamin C enhances the analgesic effect of gabapentin on rats with neuropathic pain | |
| Sundström et al. | Effects of galanin on 5-HT neurons in the rat CNS | |
| Marhuenda et al. | Antisecretory and gastroprotective effects of aescine in rats | |
| Mikulaj et al. | Endocrine functions during adaptation to stress | |
| RI et al. | The mechanisms of plant rhizome Curcuma longa action on carbohydrate metabolism in alloxan-induced diabetes mellitus rats | |
| EP0994719B1 (de) | Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen | |
| Raisman | 60 YEARS OF NEUROENDOCRINOLOGY: MEMOIR: Geoffrey Harris and my brush with his unit | |
| Houck | The resorption of sodium Dilantin-produced dermal collagen | |
| Osikov et al. | Local antioxidant effect of original dermal film with melatonin in thermal injury | |
| Barrera-Hernandez et al. | Phlorizin or vanadate treatment reverses impaired expression of albumin and hepatocyte nuclear factor 1 in diabetic rats | |
| US20160331775A1 (en) | E-selectin inhibition works in combination with low-molecular weight heparin to decrease venous thrombosis and bleeding risk | |
| Etienne et al. | Mechanisms of effect of Ginkgo biloba extract on experimental cerebral edema | |
| Gross et al. | The effect of thyroid extract, adrenalin, and a combination of these on the hearts of intact and thyroidectomized rabbits | |
| AU721141B2 (en) | Use of hyaluronidase | |
| Mei et al. | Plasma insulin in response to enterostatin and effect of adrenalectomy in rats | |
| MORIYA et al. | Inhibition of adipose tissue lipase activity following administration of vasopressin | |
| Franco et al. | Anti-ulcer activity of carbenoxolone and ISF 3401 on PGE2 release in rat gastric mucosa | |
| El-Fouly et al. | Some factors affect the degradation of (2-chloroethyl) trimethylammonium chloride by wheat plant extracts | |
| Berger et al. | Prostaglandin F2α and prostacyclin tissue levels in early phases of trypsin-induced acute pancreatitis in rats | |
| Håkanson et al. | Effect of deglycyrrhizinized liquorice on gastric acid secretion, histidine decarboxylase activity and serum gastrin level in the rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |